NCT02576574 2025-01-31
Avelumab in First-line NSCLC (JAVELIN Lung 100)
EMD Serono
Phase 3 Completed
Clinical Trials
10 trialsNCT03409458 2023-11-18
PAVE-1
Promontory Therapeutics Inc.
Phase 1/2 Completed
NCT04601402 2023-08-08
GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy
Genome & Company
Phase 1 Completed
NCT03717155 2022-06-06
Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT03270176 2022-06-01
A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
Debiopharm International SA
Phase 1 Completed
NCT03268057 2022-05-02
CLASSICAL-Lung
Vaccinex Inc.
Phase 1/2 Completed
NCT03514719 2022-01-10
PINNACLE
Radboud University Medical Center
Phase 1 Completed
NCT03158883 2021-10-20
UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients
University of California, Davis
Phase EARLY_PHASE1 Completed
NCT02222922 2020-12-17
A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT02395172 2020-08-03
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
EMD Serono
Phase 3 Completed